

Sheet 1 of 1

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Attorney Docket - P69482US1

Application No. - 10/581,547

Applicant - SCHLINGENSIEPEN et al.

Filing Date - June 2, 2006

U.S. PATENT DOCUMENTS

Examiner ¹	Ref. #	Document No.	Date	Patentee/Applicant

FOREIGN PATENT DOCUMENTS

	Country	Document No.	Translation	Abstract	Date	Patentee
	WO	01/88146 A2	<input type="checkbox"/>	<input type="checkbox"/>	9/20/2001	BIOGNOSTIK GES
	WO	99/63975 A	<input type="checkbox"/>	<input type="checkbox"/>	12/10/1999	BIOGNOSTIK GES
	WO	94/25588 A	<input type="checkbox"/>	<input type="checkbox"/>	11/10/1994	BIOGNOSTIK GES
	WO	2004/00552 A1	<input type="checkbox"/>	<input type="checkbox"/>	1/15/2004	ISIS PHARMACEUTICALS, INC.
			<input type="checkbox"/>	<input type="checkbox"/>		

NON-PATENT DOCUMENTS

Examiner ¹	Ref. #	Author (in CAPITAL LETTERS), Title, Book or Periodical, Volume, Date, Pages)
		RUBENSTEIN, M. et al., "Inhibition of PC-3 Prostate Cancer Cell Growth in Vitro Using Both Antisense Oligonucleotides and Taxol," Medical Oncology (TOTOWA), vol. 20, no. 1, 2003, pgs. 29-35
		YU D. et al., "Hybrid Oligonucleotides: Synthesis, Biophysical Properties, Stability Studies, and Biological Activity," Bioorganic & Medicinal Chemistry, vol. 4, no. 10, 1996, pgs. 1665-1692
		WOJTOWICZ-PRAGA, S., "Reversal of tumor-induced immunosuppression by TGF- β inhibitors," Investigational New Drugs, vol. 21, no. 1, February 2003, pgs. 21-32
		ARTEAGA, C. L. et al., "Reversal of Tamoxifen Resistance of Human Breast Carcinomas <i>In Vivo</i> by Neutralizing Antibodies to Transforming Growth Factor- β ," Journal of the National Cancer Institute, vol. 91, no. 1, January 6, 1999, pgs. 46-53

Examiner Signature /Scott Long/

Date Considered
06/16/2008¹Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SL/